Event dossier

FDA warns of vision loss risk linked to popular GLP-1 drugs like Wegovy, Zepbound

The agency has found evidence of a potential increased risk of a rare eye condition linked to the use of GLP-1 drugs used for weight management and diabetes. Grouped from 3 articles across 3 sources.

3 reports3 sourcesNov 10, 2026, 8:22 AM
FilterCNBC
Clustered coverageABC Australia, CNBC, Euronews
Coverage timeline3
Coverage timeline

Coverage timeline

Ranked reports inside the event cluster. Open any publisher link to read the original coverage.

CNBCNov 10, 2026, 8:22 AM

FDA warns of vision loss risk linked to popular GLP-1 drugs like Wegovy, Zepbound

The agency has found evidence of a potential increased risk of a rare eye condition linked to the use of GLP-1 drugs used for weight management and diabetes.

EuronewsNov 9, 2026, 5:19 PM

US drug watchdog orders new safety warnings for weight-loss drugs over potential risk of vision loss

The US Food and Drug Administration (FDA) is requiring manufacturers of GLP-1 medicines to update their safety labels to warn of a potential increased risk of a rare but serious eye condition that can cause permanent vision loss.

ABC AustraliaNov 9, 2026, 11:30 PM

Coming off Ozempic-like drugs linked to heart problems, study suggests

A large study suggests people with type 2 diabetes who start and then stop GLP-1 drugs may have poorer health outcomes, but more research is needed.

Related events

Related events

Nearby clusters pulled from title, summary, and keyword similarity in PostgreSQL.